Summary
Thermo Fisher Scientific Inc. (TMO) reported robust performance for the fiscal year ending December 30, 2010, with revenues reaching $10.79 billion, a 7% increase over the prior year, driven by strong demand across its Analytical Technologies and Laboratory Products and Services segments. The company demonstrated operational resilience by increasing operating income by 21% to $1.26 billion, with an improved operating margin of 11.7%. This growth was supported by strategic acquisitions, including Fermentas, Finnzymes, and Ahura Scientific, which expanded its capabilities in genomics and analytical devices, and was further bolstered by a pending acquisition of Dionex Corporation for approximately $2.1 billion. Financially, Thermo Fisher maintained a healthy liquidity position with $926 million in cash and short-term investments, and a strong operating cash flow of $1.50 billion. The company actively managed its capital structure, repurchasing $1.01 billion of its common stock while also issuing $2.2 billion in senior notes to fund acquisitions. While facing some headwinds such as currency translation impacts and the cessation of a supply contract, the company's diversified business model and strategic focus on innovation and customer productivity position it for continued growth. Investors should note the company's continued commitment to R&D, with significant investments made in this area, and its proactive approach to managing operational and financial risks.
Financial Highlights
56 data points| Revenue | $10.39B |
| Cost of Revenue | $5.26B |
| Gross Profit | $5.13B |
| R&D Expenses | $284.40M |
| SG&A Expenses | $2.73B |
| Operating Expenses | $9.21B |
| Operating Income | $1.19B |
| Interest Expense | $84.70M |
| Net Income | $1.04B |
| EPS (Basic) | $2.57 |
| EPS (Diluted) | $2.53 |
| Shares Outstanding (Basic) | 403.30M |
| Shares Outstanding (Diluted) | 409.40M |
Key Highlights
- 1Thermo Fisher Scientific reported a 7% year-over-year increase in revenue, reaching $10.79 billion for the fiscal year 2010.
- 2Operating income saw a significant 21% increase, rising to $1.26 billion, with operating margin improving to 11.7% from 10.4% in the prior year.
- 3The company completed several strategic acquisitions in 2010 (Fermentas, Finnzymes, Ahura Scientific) and announced a significant pending acquisition of Dionex Corporation for approximately $2.1 billion.
- 4Operating cash flow remained strong at $1.50 billion, indicating robust operational performance.
- 5The company actively engaged in capital allocation, repurchasing $1.01 billion in common stock and issuing $2.2 billion in senior notes.
- 6Research and Development spending was substantial, totaling $287.2 million in 2010, reflecting a commitment to innovation.
- 7The company is well-positioned to meet its financial obligations, with $926 million in cash and short-term investments and sufficient borrowing capacity.